#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-9	Psychosis	_
1-2	10-19	subgroups	_
1-3	20-26	differ	_
1-4	27-29	in	_
1-5	30-39	intrinsic	_
1-6	40-46	neural	_
1-7	47-55	activity	_
1-8	56-59	but	_
1-9	60-63	not	_
1-10	64-77	task-specific	_
1-11	78-88	processing	_
1-12	89-100	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-13	101-105	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-14	106-115	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-15	116-121	often	_
1-16	122-126	show	_
1-17	127-131	high	_
1-18	132-138	levels	_
1-19	139-141	of	_
1-20	142-151	intrinsic	_
1-21	152-153	,	_
1-22	154-156	or	_
1-23	157-168	nonspecific	_
1-24	169-170	,	_
1-25	171-177	neural	_
1-26	178-186	activity	_
1-27	187-188	,	_
1-28	189-192	but	_
1-29	193-203	attenuated	_
1-30	204-221	stimulus-specific	_
1-31	222-230	activity	_
1-32	231-232	.	_

2-1	233-241	proposed	_
2-2	242-246	that	_
2-3	247-250	one	_
2-4	251-259	subgroup	_
2-5	260-262	of	_
2-6	263-272	psychosis	_
2-7	273-278	cases	_
2-8	279-282	has	_
2-9	283-294	accentuated	_
2-10	295-304	intrinsic	_
2-11	305-313	activity	_
2-12	314-315	(	_
2-13	316-325	Biotype-2	_
2-14	326-327	’	_
2-15	328-329	s	_
2-16	330-331	)	_
2-17	332-335	and	_
2-18	336-337	a	_
2-19	338-347	different	_
2-20	348-356	subgroup	_
2-21	357-358	(	_
2-22	359-368	Biotype-1	_
2-23	369-370	’	_
2-24	371-372	s	_
2-25	373-374	)	_
2-26	375-378	has	_
2-27	379-389	diminished	_
2-28	390-399	intrinsic	_
2-29	400-408	activity	_
2-30	409-410	,	_
2-31	411-415	with	_
2-32	416-420	both	_
2-33	421-427	groups	_
2-34	428-438	exhibiting	_
2-35	439-446	varying	_
2-36	447-454	degrees	_
2-37	455-457	of	_
2-38	458-467	cognitive	_
2-39	468-476	deficits	_
2-40	477-478	.	_

3-1	479-483	This	_
3-2	484-489	model	_
3-3	490-493	was	_
3-4	494-501	studied	_
3-5	502-504	by	_
3-6	505-514	assessing	_
3-7	515-521	neural	_
3-8	522-530	activity	_
3-9	531-533	in	_
3-10	534-543	psychosis	_
3-11	544-552	probands	_
3-12	553-554	(	_
3-13	555-560	N=105	_
3-14	561-562	)	_
3-15	563-569	during	_
3-16	570-578	baseline	_
3-17	579-582	and	_
3-18	583-584	a	_
3-19	585-589	5sec	_
3-20	590-596	period	_
3-21	597-599	in	_
3-22	600-611	preparation	_
3-23	612-615	for	_
3-24	616-617	a	_
3-25	618-635	pro-/anti-saccade	_
3-26	636-640	task	_
3-27	641-642	.	_

4-1	643-655	Steady-state	_
4-2	656-663	stimuli	_
4-3	664-671	allowed	_
4-4	672-681	real-time	_
4-5	682-692	assessment	_
4-6	693-695	of	_
4-7	696-706	modulation	_
4-8	707-709	of	_
4-9	710-723	visuocortical	_
4-10	724-734	investment	_
4-11	735-737	to	_
4-12	738-747	different	_
4-13	748-754	target	_
4-14	755-764	locations	_
4-15	765-766	.	_

5-1	767-776	Psychosis	_
5-2	777-785	probands	_
5-3	786-788	as	_
5-4	789-790	a	_
5-5	791-796	whole	_
5-6	797-803	showed	_
5-7	804-808	poor	_
5-8	809-820	antisaccade	_
5-9	821-832	performance	_
5-10	833-834	.	_

6-1	835-837	As	_
6-2	838-846	expected	_
6-3	847-848	,	_
6-4	849-858	Biotype-1	_
6-5	859-865	showed	_
6-6	866-876	diminished	_
6-7	877-886	intrinsic	_
6-8	887-893	neural	_
6-9	894-902	activity	_
6-10	903-906	and	_
6-11	907-910	the	_
6-12	911-916	worst	_
6-13	917-925	behavior	_
6-14	926-927	,	_
6-15	928-931	and	_
6-16	932-941	Biotype-2	_
6-17	942-948	showed	_
6-18	949-960	accentuated	_
6-19	961-970	intrinsic	_
6-20	971-979	activity	_
6-21	980-983	and	_
6-22	984-988	less	_
6-23	989-996	deviant	_
6-24	997-1005	behavior	_
6-25	1006-1007	.	_

7-1	1008-1012	Both	_
7-2	1013-1015	of	_
7-3	1016-1021	these	_
7-4	1022-1028	groups	_
7-5	1029-1033	also	_
7-6	1034-1043	exhibited	_
7-7	1044-1048	less	_
7-8	1049-1056	dynamic	_
7-9	1057-1068	oscillatory	_
7-10	1069-1074	phase	_
7-11	1075-1084	synchrony	_
7-12	1085-1086	.	_

8-1	1087-1096	Biotype-3	_
8-2	1097-1103	showed	_
8-3	1104-1106	no	_
8-4	1107-1125	neurophysiological	_
8-5	1126-1137	differences	_
8-6	1138-1142	from	_
8-7	1143-1150	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-8	1151-1162	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-9	1163-1164	,	_
8-10	1165-1172	despite	_
8-11	1173-1174	a	_
8-12	1175-1182	history	_
8-13	1183-1185	of	_
8-14	1186-1195	psychosis	_
8-15	1196-1197	.	_

9-1	1198-1211	Interestingly	_
9-2	1212-1213	,	_
9-3	1214-1217	all	_
9-4	1218-1227	psychosis	_
9-5	1228-1237	subgroups	_
9-6	1238-1244	showed	_
9-7	1245-1251	normal	_
9-8	1252-1253	(	_
9-9	1254-1258	i.e.	_
9-10	1259-1260	,	_
9-11	1261-1264	not	_
9-12	1265-1274	different	_
9-13	1275-1279	from	_
9-14	1280-1287	healthy	_
9-15	1288-1289	)	_
9-16	1290-1301	preparatory	_
9-17	1302-1312	modulation	_
9-18	1313-1315	of	_
9-19	1316-1329	visuocortical	_
9-20	1330-1340	investment	_
9-21	1341-1343	as	_
9-22	1344-1345	a	_
9-23	1346-1354	function	_
9-24	1355-1357	of	_
9-25	1358-1367	cognitive	_
9-26	1368-1375	demands	_
9-27	1376-1377	,	_
9-28	1378-1385	despite	_
9-29	1386-1393	varying	_
9-30	1394-1400	levels	_
9-31	1401-1403	of	_
9-32	1404-1408	task	_
9-33	1409-1420	performance	_
9-34	1421-1422	.	_

10-1	1423-1430	Similar	_
10-2	1431-1439	analyses	_
10-3	1440-1449	conducted	_
10-4	1450-1461	subgrouping	_
10-5	1462-1467	cases	_
10-6	1468-1470	by	_
10-7	1471-1480	psychotic	_
10-8	1481-1495	symptomatology	_
10-9	1496-1504	revealed	_
10-10	1505-1510	fewer	_
10-11	1511-1514	and	_
10-12	1515-1519	less	_
10-13	1520-1530	consistent	_
10-14	1531-1542	differences	_
10-15	1543-1544	,	_
10-16	1545-1554	including	_
10-17	1555-1557	no	_
10-18	1558-1567	intrinsic	_
10-19	1568-1576	activity	_
10-20	1577-1588	differences	_
10-21	1589-1596	between	_
10-22	1597-1600	any	_
10-23	1601-1609	clinical	_
10-24	1610-1618	subgroup	_
10-25	1619-1622	and	_
10-26	1623-1630	healthy	_
10-27	1631-1642	individuals	_
10-28	1643-1644	.	_

11-1	1645-1649	This	_
11-2	1650-1655	study	_
11-3	1656-1667	illustrates	_
11-4	1668-1672	that	_
11-5	1673-1674	(	_
11-6	1675-1676	i	_
11-7	1677-1678	)	_
11-8	1679-1690	differences	_
11-9	1691-1693	in	_
11-10	1694-1703	intrinsic	_
11-11	1704-1710	neural	_
11-12	1711-1719	activity	_
11-13	1720-1723	may	_
11-14	1724-1726	be	_
11-15	1727-1728	a	_
11-16	1729-1740	fundamental	_
11-17	1741-1755	characteristic	_
11-18	1756-1758	of	_
11-19	1759-1768	psychosis	_
11-20	1769-1772	and	_
11-21	1773-1777	need	_
11-22	1778-1780	to	_
11-23	1781-1783	be	_
11-24	1784-1793	evaluated	_
11-25	1794-1804	separately	_
11-26	1805-1809	from	_
11-27	1810-1827	stimulus-specific	_
11-28	1828-1837	responses	_
11-29	1838-1839	,	_
11-30	1840-1843	and	_
11-31	1844-1845	(	_
11-32	1846-1848	ii	_
11-33	1849-1850	)	_
11-34	1851-1859	grouping	_
11-35	1860-1868	patients	_
11-36	1869-1874	based	_
11-37	1875-1877	on	_
11-38	1878-1894	multidimensional	_
11-39	1895-1909	classification	_
11-40	1910-1915	using	_
11-41	1916-1931	neurobiological	_
11-42	1932-1936	data	_
11-43	1937-1940	may	_
11-44	1941-1945	have	_
11-45	1946-1956	advantages	_
11-46	1957-1960	for	_
11-47	1961-1970	resolving	_
11-48	1971-1984	heterogeneity	_
11-49	1985-1988	and	_
11-50	1989-1999	clarifying	_
11-51	2000-2007	illness	_
11-52	2008-2018	mechanisms	_
11-53	2019-2027	relative	_
11-54	2028-2030	to	_
11-55	2031-2042	traditional	_
11-56	2043-2054	psychiatric	_
11-57	2055-2064	diagnoses	_
11-58	2065-2066	.	_

12-1	2067-2068	2	_
12-2	2069-2070	.	_

13-1	2071-2078	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-2	2079-2082	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-3	2083-2092	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-4	2093-2096	2.1	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-5	2097-2098	.	_

14-1	2099-2111	Participants	_
14-2	2112-2114	As	_
14-3	2115-2116	a	_
14-4	2117-2121	part	_
14-5	2122-2124	of	_
14-6	2125-2126	a	_
14-7	2127-2136	multisite	_
14-8	2137-2141	data	_
14-9	2142-2152	collection	_
14-10	2153-2160	project	_
14-11	2161-2162	,	_
14-12	2163-2166	the	_
14-13	2167-2188	Bipolar-Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-14	2189-2196	Network	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-15	2197-2199	on	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-16	2200-2212	Intermediate	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-17	2213-2223	Phenotypes	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-18	2224-2225	(	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-19	2226-2232	B-SNIP	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-20	2233-2234	)	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-21	2235-2236	,	_
14-22	2237-2245	subjects	_
14-23	2246-2250	were	_
14-24	2251-2260	recruited	_
14-25	2261-2262	,	_
14-26	2263-2274	interviewed	_
14-27	2275-2276	,	_
14-28	2277-2280	and	_
14-29	2281-2287	tested	_
14-30	2288-2291	for	_
14-31	2292-2295	the	_
14-32	2296-2303	present	_
14-33	2304-2309	study	_
14-34	2310-2312	at	_
14-35	2313-2316	the	_
14-36	2317-2327	University	_
14-37	2328-2330	of	_
14-38	2331-2347	Illinois-Chicago	_
14-39	2348-2352	site	_
14-40	2353-2354	.	_

15-1	2355-2365	Clinically	_
15-2	2366-2372	stable	_
15-3	2373-2382	psychosis	_
15-4	2383-2391	probands	_
15-5	2392-2393	(	_
15-6	2394-2395	N	_
15-7	2396-2397	=	_
15-8	2398-2401	105	_
15-9	2402-2403	)	_
15-10	2404-2407	and	_
15-11	2408-2415	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-12	2416-2426	comparison	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-13	2427-2435	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-14	2436-2437	(	_
15-15	2438-2440	HC	_
15-16	2441-2442	;	_
15-17	2443-2444	N	_
15-18	2445-2448	=50	_
15-19	2449-2450	)	_
15-20	2451-2455	were	_
15-21	2456-2465	recruited	_
15-22	2466-2469	via	_
15-23	2470-2479	community	_
15-24	2480-2494	advertisements	_
15-25	2495-2496	,	_
15-26	2497-2503	linked	_
15-27	2504-2513	community	_
15-28	2514-2524	facilities	_
15-29	2525-2528	and	_
15-30	2529-2537	programs	_
15-31	2538-2539	,	_
15-32	2540-2543	and	_
15-33	2544-2550	family	_
15-34	2551-2558	support	_
15-35	2559-2565	groups	_
15-36	2566-2567	(	_
15-37	2568-2571	see	_
15-38	2572-2577	Table	_
15-39	2578-2579	1	_
15-40	2580-2583	and	_
15-41	2584-2596	Supplemental	_
15-42	2597-2602	Table	_
15-43	2603-2604	1	_
15-44	2605-2608	and	_
15-45	2609-2610	2	_
15-46	2611-2614	for	_
15-47	2615-2623	clinical	_
15-48	2624-2627	and	_
15-49	2628-2639	demographic	_
15-50	2640-2651	information	_
15-51	2652-2653	)	_
15-52	2654-2655	.	_

16-1	2656-2664	Clinical	_
16-2	2665-2674	diagnosis	_
16-3	2675-2678	was	_
16-4	2679-2689	determined	_
16-5	2690-2697	through	_
16-6	2698-2712	administration	_
16-7	2713-2715	of	_
16-8	2716-2719	the	_
16-9	2720-2730	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-10	2731-2739	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-11	2740-2749	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-12	2750-2753	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-13	2754-2760	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-14	2761-2770	Diagnosis	_
16-15	2771-2774	and	_
16-16	2775-2784	consensus	_
16-17	2785-2795	diagnostic	_
16-18	2796-2802	review	_
16-19	2803-2804	;	_
16-20	2805-2808	see	_
16-21	2809-2812	for	_
16-22	2813-2821	clinical	_
16-23	2822-2832	evaluation	_
16-24	2833-2840	details	_
16-25	2841-2842	.	_

17-1	2843-2845	HC	_
17-2	2846-2849	had	_
17-3	2850-2852	no	_
17-4	2853-2861	personal	_
17-5	2862-2869	history	_
17-6	2870-2872	of	_
17-7	2873-2882	psychotic	_
17-8	2883-2884	,	_
17-9	2885-2892	bipolar	_
17-10	2893-2894	,	_
17-11	2895-2897	or	_
17-12	2898-2907	recurrent	_
17-13	2908-2913	major	_
17-14	2914-2924	depressive	_
17-15	2925-2933	disorder	_
17-16	2934-2935	,	_
17-17	2936-2938	or	_
17-18	2939-2940	a	_
17-19	2941-2947	family	_
17-20	2948-2955	history	_
17-21	2956-2958	of	_
17-22	2959-2980	schizophrenia-bipolar	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
17-23	2981-2989	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
17-24	2990-2999	disorders	_
17-25	3000-3002	in	_
17-26	3003-3008	first	_
17-27	3009-3011	or	_
17-28	3012-3018	second	_
17-29	3019-3025	degree	_
17-30	3026-3035	relatives	_
17-31	3036-3037	.	_

18-1	3038-3041	All	_
18-2	3042-3050	subjects	_
18-3	3051-3059	provided	_
18-4	3060-3067	written	_
18-5	3068-3075	consent	_
18-6	3076-3082	before	_
18-7	3083-3096	participating	_
18-8	3097-3098	,	_
18-9	3099-3102	and	_
18-10	3103-3106	the	_
18-11	3107-3112	study	_
18-12	3113-3116	was	_
18-13	3117-3125	approved	_
18-14	3126-3128	by	_
18-15	3129-3132	the	_
18-16	3133-3143	University	_
18-17	3144-3146	of	_
18-18	3147-3163	Illinois-Chicago	_
18-19	3164-3177	Institutional	_
18-20	3178-3184	Review	_
18-21	3185-3190	Board	_
18-22	3191-3192	.	_

19-1	3193-3197	used	_
19-2	3198-3207	biomarker	_
19-3	3208-3212	data	_
19-4	3213-3215	to	_
19-5	3216-3224	classify	_
19-6	3225-3234	psychosis	_
19-7	3235-3240	cases	_
19-8	3241-3245	into	_
19-9	3246-3254	Biotypes	_
19-10	3255-3256	.	_

20-1	3257-3266	Biotype-1	_
20-2	3267-3270	was	_
20-3	3271-3275	most	_
20-4	3276-3287	reminiscent	_
20-5	3288-3290	of	_
20-6	3291-3303	poor-outcome	_
20-7	3304-3305	,	_
20-8	3306-3313	chronic	_
20-9	3314-3315	,	_
20-10	3316-3319	and	_
20-11	3320-3337	neurobiologically	_
20-12	3338-3346	impaired	_
20-13	3347-3356	psychosis	_
20-14	3357-3362	cases	_
20-15	3363-3364	;	_
20-16	3365-3374	Biotype-2	_
20-17	3375-3378	was	_
20-18	3379-3392	characterized	_
20-19	3393-3395	by	_
20-20	3396-3416	hyper-responsiveness	_
20-21	3417-3419	to	_
20-22	3420-3432	sensorimotor	_
20-23	3433-3439	events	_
20-24	3440-3441	,	_
20-25	3442-3447	while	_
20-26	3448-3457	Biotype-3	_
20-27	3458-3461	was	_
20-28	3462-3468	closer	_
20-29	3469-3471	to	_
20-30	3472-3474	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
20-31	3475-3479	than	_
20-32	3480-3482	to	_
20-33	3483-3486	the	_
20-34	3487-3492	other	_
20-35	3493-3500	Biotype	_
20-36	3501-3510	subgroups	_
20-37	3511-3517	across	_
20-38	3518-3528	biomarkers	_
20-39	3529-3530	(	_
20-40	3531-3538	despite	_
20-41	3539-3547	presence	_
20-42	3548-3550	of	_
20-43	3551-3560	psychosis	_
20-44	3561-3562	)	_
20-45	3563-3564	,	_
20-46	3565-3573	although	_
20-47	3574-3578	they	_
20-48	3579-3584	still	_
20-49	3585-3588	had	_
20-50	3589-3595	modest	_
20-51	3596-3606	deviations	_
20-52	3607-3609	on	_
20-53	3610-3618	multiple	_
20-54	3619-3629	biomarkers	_
20-55	3630-3631	.	_

21-1	3632-3635	All	_
21-2	3636-3648	participants	_
21-3	3649-3651	in	_
21-4	3652-3655	the	_
21-5	3656-3663	current	_
21-6	3664-3669	study	_
21-7	3670-3674	were	_
21-8	3675-3683	included	_
21-9	3684-3686	in	_
21-10	3687-3688	,	_
21-11	3689-3692	and	_
21-12	3693-3695	so	_
21-13	3696-3701	their	_
21-14	3702-3709	current	_
21-15	3710-3717	Biotype	_
21-16	3718-3728	membership	_
21-17	3729-3730	(	_
21-18	3731-3740	Biotype-1	_
21-19	3741-3742	,	_
21-20	3743-3747	N=20	_
21-21	3748-3749	;	_
21-22	3750-3759	Biotype-2	_
21-23	3760-3761	,	_
21-24	3762-3766	N=30	_
21-25	3767-3768	;	_
21-26	3769-3778	Biotype-3	_
21-27	3779-3780	,	_
21-28	3781-3785	N=55	_
21-29	3786-3787	)	_
21-30	3788-3790	is	_
21-31	3791-3796	known	_
21-32	3797-3798	.	_

22-1	3799-3802	The	_
22-2	3803-3807	data	_
22-3	3808-3812	used	_
22-4	3813-3816	for	_
22-5	3817-3827	developing	_
22-6	3828-3836	Biotypes	_
22-7	3837-3840	was	_
22-8	3841-3852	independent	_
22-9	3853-3854	,	_
22-10	3855-3862	however	_
22-11	3863-3864	,	_
22-12	3865-3869	from	_
22-13	3870-3875	tasks	_
22-14	3876-3879	and	_
22-15	3880-3892	measurements	_
22-16	3893-3901	obtained	_
22-17	3902-3905	for	_
22-18	3906-3909	the	_
22-19	3910-3917	present	_
22-20	3918-3923	study	_
22-21	3924-3925	(	_
22-22	3926-3929	see	_
22-23	3930-3942	Supplemental	_
22-24	3943-3952	Materials	_
22-25	3953-3954	)	_
22-26	3955-3956	.	_

23-1	3957-3960	The	_
23-2	3961-3968	current	_
23-3	3969-3973	data	_
23-4	3974-3978	were	_
23-5	3979-3988	collected	_
23-6	3989-3991	as	_
23-7	3992-3996	part	_
23-8	3997-3999	of	_
23-9	4000-4001	a	_
23-10	4002-4008	series	_
23-11	4009-4011	of	_
23-12	4012-4025	complimentary	_
23-13	4026-4035	paradigms	_
23-14	4036-4038	on	_
23-15	4039-4042	the	_
23-16	4043-4047	same	_
23-17	4048-4054	sample	_
23-18	4055-4057	as	_
23-19	4058-4066	reported	_
23-20	4067-4069	in	_
23-21	4070-4071	.	_

24-1	4072-4078	Sample	_
24-2	4079-4083	size	_
24-3	4084-4095	differences	_
24-4	4096-4099	are	_
24-5	4100-4103	due	_
24-6	4104-4106	to	_
24-7	4107-4110	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
24-8	4111-4115	data	_
24-9	4116-4123	quality	_
24-10	4124-4125	.	_

25-1	4126-4129	The	_
25-2	4130-4139	recording	_
25-3	4140-4143	and	_
25-4	4144-4157	preprocessing	_
25-5	4158-4160	of	_
25-6	4161-4164	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
25-7	4165-4169	data	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
25-8	4170-4174	were	_
25-9	4175-4184	identical	_
25-10	4185-4187	to	_
25-11	4188-4192	that	_
25-12	4193-4195	in	_
25-13	4196-4204	previous	_
25-14	4205-4209	work	_
25-15	4210-4211	(	_
25-16	4212-4213	;	_
25-17	4214-4218	also	_
25-18	4219-4222	see	_
25-19	4223-4235	Supplemental	_
25-20	4236-4245	Materials	_
25-21	4246-4247	)	_
25-22	4248-4249	,	_
25-23	4250-4256	except	_
25-24	4257-4261	that	_
25-25	4262-4266	here	_
25-26	4267-4270	the	_
25-27	4271-4275	data	_
25-28	4276-4280	were	_
25-29	4281-4285	kept	_
25-30	4286-4288	at	_
25-31	4289-4292	the	_
25-32	4293-4301	original	_
25-33	4302-4310	sampling	_
25-34	4311-4315	rate	_
25-35	4316-4318	of	_
25-36	4319-4323	1000	_
25-37	4324-4326	Hz	_
25-38	4327-4328	.	_

26-1	4329-4332	2.2	_
26-2	4333-4334	.	_

27-1	4335-4342	Stimuli	_
27-2	4343-4350	Stimuli	_
27-3	4351-4355	were	_
27-4	4356-4365	presented	_
27-5	4366-4368	on	_
27-6	4369-4370	a	_
27-7	4371-4378	19-inch	_
27-8	4379-4391	flat-surface	_
27-9	4392-4400	computer	_
27-10	4401-4408	monitor	_
27-11	4409-4413	with	_
27-12	4414-4415	a	_
27-13	4416-4423	refresh	_
27-14	4424-4428	rate	_
27-15	4429-4431	of	_
27-16	4432-4436	60Hz	_
27-17	4437-4438	.	_

28-1	4439-4446	Stimuli	_
28-2	4447-4456	consisted	_
28-3	4457-4459	of	_
28-4	4460-4465	three	_
28-5	4466-4471	5×5cm	_
28-6	4472-4485	checkerboards	_
28-7	4486-4487	(	_
28-8	4488-4499	alternating	_
28-9	4500-4507	colored	_
28-10	4508-4511	and	_
28-11	4512-4517	black	_
28-12	4518-4525	squares	_
28-13	4526-4527	,	_
28-14	4528-4532	each	_
28-15	4533-4537	1deg	_
28-16	4538-4544	square	_
28-17	4545-4546	)	_
28-18	4547-4554	located	_
28-19	4555-4557	at	_
28-20	4558-4565	central	_
28-21	4566-4574	fixation	_
28-22	4575-4578	and	_
28-23	4579-4580	8	_
28-24	4581-4584	deg	_
28-25	4585-4587	to	_
28-26	4588-4591	the	_
28-27	4592-4596	left	_
28-28	4597-4600	and	_
28-29	4601-4606	right	_
28-30	4607-4609	of	_
28-31	4610-4617	central	_
28-32	4618-4626	fixation	_
28-33	4627-4628	(	_
28-34	4629-4635	Figure	_
28-35	4636-4637	1	_
28-36	4638-4639	)	_
28-37	4640-4641	.	_

29-1	4642-4655	Checkerboards	_
29-2	4656-4660	were	_
29-3	4661-4667	either	_
29-4	4668-4673	green	_
29-5	4674-4675	(	_
29-6	4676-4682	during	_
29-7	4683-4686	the	_
29-8	4687-4697	prosaccade	_
29-9	4698-4703	block	_
29-10	4704-4705	)	_
29-11	4706-4708	or	_
29-12	4709-4712	red	_
29-13	4713-4714	(	_
29-14	4715-4721	during	_
29-15	4722-4725	the	_
29-16	4726-4737	antisaccade	_
29-17	4738-4743	block	_
29-18	4744-4745	)	_
29-19	4746-4747	.	_

30-1	4748-4752	Both	_
30-2	4753-4759	colors	_
30-3	4760-4763	had	_
30-4	4764-4769	equal	_
30-5	4770-4779	luminance	_
30-6	4780-4781	(	_
30-7	4782-4783	5	_
30-8	4784-4789	cd/m2	_
30-9	4790-4791	)	_
30-10	4792-4793	.	_

31-1	4794-4797	The	_
31-2	4798-4808	peripheral	_
31-3	4809-4822	checkerboards	_
31-4	4823-4827	were	_
31-5	4828-4837	luminance	_
31-6	4838-4847	modulated	_
31-7	4848-4849	(	_
31-8	4850-4853	100	_
31-9	4854-4855	%	_
31-10	4856-4866	modulation	_
31-11	4867-4872	depth	_
31-12	4873-4874	)	_
31-13	4875-4877	at	_
31-14	4878-4881	two	_
31-15	4882-4892	flickering	_
31-16	4893-4904	frequencies	_
31-17	4905-4906	(	_
31-18	4907-4911	12Hz	_
31-19	4912-4914	in	_
31-20	4915-4918	the	_
31-21	4919-4923	left	_
31-22	4924-4930	visual	_
31-23	4931-4936	field	_
31-24	4937-4938	,	_
31-25	4939-4943	15Hz	_
31-26	4944-4946	in	_
31-27	4947-4950	the	_
31-28	4951-4956	right	_
31-29	4957-4963	visual	_
31-30	4964-4969	field	_
31-31	4970-4971	)	_
31-32	4972-4973	,	_
31-33	4974-4978	with	_
31-34	4979-4982	the	_
31-35	4983-4990	central	_
31-36	4991-5003	checkerboard	_
31-37	5004-5007	not	_
31-38	5008-5018	flickering	_
31-39	5019-5020	.	_

32-1	5021-5027	Blocks	_
32-2	5028-5037	consisted	_
32-3	5038-5040	of	_
32-4	5041-5043	50	_
32-5	5044-5050	trials	_
32-6	5051-5053	of	_
32-7	5054-5060	either	_
32-8	5061-5065	pro-	_
32-9	5066-5068	or	_
32-10	5069-5082	anti-saccades	_
32-11	5083-5084	,	_
32-12	5085-5088	for	_
32-13	5089-5090	a	_
32-14	5091-5096	total	_
32-15	5097-5099	of	_
32-16	5100-5103	100	_
32-17	5104-5110	trials	_
32-18	5111-5112	.	_

33-1	5113-5117	Each	_
33-2	5118-5123	trial	_
33-3	5124-5127	was	_
33-4	5128-5136	preceded	_
33-5	5137-5139	by	_
33-6	5140-5142	an	_
33-7	5143-5154	inter-trial	_
33-8	5155-5163	interval	_
33-9	5164-5166	of	_
33-10	5167-5171	6sec	_
33-11	5172-5173	,	_
33-12	5174-5176	in	_
33-13	5177-5182	which	_
33-14	5183-5184	a	_
33-15	5185-5189	gray	_
33-16	5190-5197	central	_
33-17	5198-5206	fixation	_
33-18	5207-5213	square	_
33-19	5214-5215	(	_
33-20	5216-5217	1	_
33-21	5218-5221	deg	_
33-22	5222-5228	square	_
33-23	5229-5230	)	_
33-24	5231-5234	was	_
33-25	5235-5244	presented	_
33-26	5245-5246	.	_

34-1	5247-5249	At	_
34-2	5250-5254	each	_
34-3	5255-5262	quarter	_
34-4	5263-5265	of	_
34-5	5266-5270	this	_
34-6	5271-5279	Fixation	_
34-7	5280-5286	Period	_
34-8	5287-5288	(	_
34-9	5289-5295	1.5sec	_
34-10	5296-5297	)	_
34-11	5298-5299	,	_
34-12	5300-5303	the	_
34-13	5304-5311	central	_
34-14	5312-5318	square	_
34-15	5319-5328	decreased	_
34-16	5329-5331	in	_
34-17	5332-5336	size	_
34-18	5337-5339	by	_
34-19	5340-5341	¼	_
34-20	5342-5344	in	_
34-21	5345-5350	order	_
34-22	5351-5353	to	_
34-23	5354-5358	give	_
34-24	5359-5360	a	_
34-25	5361-5362	“	_
34-26	5363-5372	countdown	_
34-27	5373-5374	”	_
34-28	5375-5377	to	_
34-29	5378-5381	the	_
34-30	5382-5386	next	_
34-31	5387-5392	trial	_
34-32	5393-5394	.	_

35-1	5395-5401	Trials	_
35-2	5402-5407	began	_
35-3	5408-5412	with	_
35-4	5413-5416	the	_
35-5	5417-5427	peripheral	_
35-6	5428-5441	checkerboards	_
35-7	5442-5452	flickering	_
35-8	5453-5456	for	_
35-9	5457-5458	5	_
35-10	5459-5462	sec	_
35-11	5463-5464	.	_

36-1	5465-5477	Participants	_
36-2	5478-5482	were	_
36-3	5483-5493	instructed	_
36-4	5494-5496	to	_
36-5	5497-5505	maintain	_
36-6	5506-5514	fixation	_
36-7	5515-5517	on	_
36-8	5518-5521	the	_
36-9	5522-5529	central	_
36-10	5530-5542	checkerboard	_
36-11	5543-5553	throughout	_
36-12	5554-5558	this	_
36-13	5559-5570	Preparatory	_
36-14	5571-5577	Period	_
36-15	5578-5579	.	_

37-1	5580-5587	Similar	_
37-2	5588-5590	to	_
37-3	5591-5594	the	_
37-4	5595-5603	Fixation	_
37-5	5604-5610	Period	_
37-6	5611-5612	,	_
37-7	5613-5615	at	_
37-8	5616-5620	1sec	_
37-9	5621-5630	intervals	_
37-10	5631-5637	during	_
37-11	5638-5641	the	_
37-12	5642-5653	Preparatory	_
37-13	5654-5660	Period	_
37-14	5661-5664	the	_
37-15	5665-5671	center	_
37-16	5672-5678	square	_
37-17	5679-5681	of	_
37-18	5682-5685	the	_
37-19	5686-5693	central	_
37-20	5694-5706	checkerboard	_
37-21	5707-5716	decreased	_
37-22	5717-5719	in	_
37-23	5720-5724	size	_
37-24	5725-5727	by	_
37-25	5728-5729	¼	_
37-26	5730-5732	in	_
37-27	5733-5738	order	_
37-28	5739-5741	to	_
37-29	5742-5746	give	_
37-30	5747-5750	the	_
37-31	5751-5763	participants	_
37-32	5764-5775	information	_
37-33	5776-5781	about	_
37-34	5782-5785	the	_
37-35	5786-5795	impending	_
37-36	5796-5804	response	_
37-37	5805-5816	requirement	_
37-38	5817-5818	.	_

38-1	5819-5824	After	_
38-2	5825-5828	the	_
38-3	5829-5833	5sec	_
38-4	5834-5845	Preparatory	_
38-5	5846-5852	Period	_
38-6	5853-5854	,	_
38-7	5855-5858	one	_
38-8	5859-5861	of	_
38-9	5862-5865	the	_
38-10	5866-5876	peripheral	_
38-11	5877-5890	checkerboards	_
38-12	5891-5892	(	_
38-13	5893-5908	pseudo-randomly	_
38-14	5909-5919	determined	_
38-15	5920-5921	)	_
38-16	5922-5931	increased	_
38-17	5932-5934	in	_
38-18	5935-5944	luminance	_
38-19	5945-5947	to	_
38-20	5948-5950	20	_
38-21	5951-5956	cd/m2	_
38-22	5957-5960	for	_
38-23	5961-5968	1.25sec	_
38-24	5969-5970	(	_
38-25	5971-5974	the	_
38-26	5975-5983	saccadic	_
38-27	5984-5992	Response	_
38-28	5993-5999	Period	_
38-29	6000-6001	)	_
38-30	6002-6003	,	_
38-31	6004-6009	while	_
38-32	6010-6014	both	_
38-33	6015-6025	peripheral	_
38-34	6026-6039	checkerboards	_
38-35	6040-6049	continued	_
38-36	6050-6060	flickering	_
38-37	6061-6062	.	_

39-1	6063-6065	On	_
39-2	6066-6076	prosaccade	_
39-3	6077-6083	trials	_
39-4	6084-6085	,	_
39-5	6086-6098	participants	_
39-6	6099-6103	were	_
39-7	6104-6106	to	_
39-8	6107-6111	look	_
39-9	6112-6114	as	_
39-10	6115-6122	quickly	_
39-11	6123-6126	and	_
39-12	6127-6137	accurately	_
39-13	6138-6140	as	_
39-14	6141-6149	possible	_
39-15	6150-6156	toward	_
39-16	6157-6161	this	_
39-17	6162-6168	target	_
39-18	6169-6170	;	_
39-19	6171-6173	on	_
39-20	6174-6185	antisaccade	_
39-21	6186-6192	trials	_
39-22	6193-6194	,	_
39-23	6195-6207	participants	_
39-24	6208-6212	were	_
39-25	6213-6223	instructed	_
39-26	6224-6226	to	_
39-27	6227-6231	look	_
39-28	6232-6234	as	_
39-29	6235-6242	quickly	_
39-30	6243-6246	and	_
39-31	6247-6257	accurately	_
39-32	6258-6260	as	_
39-33	6261-6269	possible	_
39-34	6270-6272	to	_
39-35	6273-6276	the	_
39-36	6277-6283	mirror	_
39-37	6284-6289	image	_
39-38	6290-6298	location	_
39-39	6299-6300	(	_
39-40	6301-6309	opposite	_
39-41	6310-6322	checkerboard	_
39-42	6323-6324	)	_
39-43	6325-6326	.	_

40-1	6327-6330	All	_
40-2	6331-6339	analyses	_
40-3	6340-6344	were	_
40-4	6345-6356	time-locked	_
40-5	6357-6359	to	_
40-6	6360-6363	the	_
40-7	6364-6369	onset	_
40-8	6370-6372	of	_
40-9	6373-6376	the	_
40-10	6377-6388	Preparatory	_
40-11	6389-6395	Period	_
40-12	6396-6397	,	_
40-13	6398-6401	and	_
40-14	6402-6414	descriptions	_
40-15	6415-6420	below	_
40-16	6421-6422	(	_
40-17	6423-6427	e.g.	_
40-18	6428-6429	,	_
40-19	6430-6433	pre	_
40-20	6434-6436	or	_
40-21	6437-6441	post	_
40-22	6442-6450	stimulus	_
40-23	6451-6456	onset	_
40-24	6457-6458	)	_
40-25	6459-6466	reflect	_
40-26	6467-6471	this	_
40-27	6472-6473	.	_

41-1	6474-6476	As	_
41-2	6477-6480	the	_
41-3	6481-6488	primary	_
41-4	6489-6497	interest	_
41-5	6498-6500	of	_
41-6	6501-6505	this	_
41-7	6506-6511	study	_
41-8	6512-6515	was	_
41-9	6516-6527	preparatory	_
41-10	6528-6538	modulation	_
41-11	6539-6540	,	_
41-12	6541-6549	analyses	_
41-13	6550-6552	do	_
41-14	6553-6556	not	_
41-15	6557-6564	include	_
41-16	6565-6568	any	_
41-17	6569-6574	brain	_
41-18	6575-6579	data	_
41-19	6580-6584	from	_
41-20	6585-6588	the	_
41-21	6589-6597	Response	_
41-22	6598-6604	Period	_
41-23	6605-6606	.	_

42-1	6607-6610	2.3	_
42-2	6611-6612	.	_

43-1	6613-6617	Data	_
43-2	6618-6626	Analyses	_
43-3	6627-6630	Two	_
43-4	6631-6641	approaches	_
43-5	6642-6646	were	_
43-6	6647-6651	used	_
43-7	6652-6654	to	_
43-8	6655-6663	quantify	_
43-9	6664-6669	brain	_
43-10	6670-6678	activity	_
43-11	6679-6680	.	_

44-1	6681-6686	First	_
44-2	6687-6688	,	_
44-3	6689-6695	evoked	_
44-4	6696-6706	potentials	_
44-5	6707-6711	were	_
44-6	6712-6716	used	_
44-7	6717-6719	to	_
44-8	6720-6728	evaluate	_
44-9	6729-6732	the	_
44-10	6733-6742	amplitude	_
44-11	6743-6746	and	_
44-12	6747-6754	spatial	_
44-13	6755-6767	distribution	_
44-14	6768-6770	of	_
44-15	6771-6776	brain	_
44-16	6777-6785	activity	_
44-17	6786-6788	at	_
44-18	6789-6792	the	_
44-19	6793-6798	onset	_
44-20	6799-6801	of	_
44-21	6802-6808	visual	_
44-22	6809-6820	stimulation	_
44-23	6821-6822	(	_
44-24	6823-6825	at	_
44-25	6826-6829	the	_
44-26	6830-6839	beginning	_
44-27	6840-6842	of	_
44-28	6843-6846	the	_
44-29	6847-6858	Preparatory	_
44-30	6859-6865	Period	_
44-31	6866-6867	,	_
44-32	6868-6874	before	_
44-33	6875-6888	stabilization	_
44-34	6889-6891	of	_
44-35	6892-6895	the	_
44-36	6896-6908	steady-state	_
44-37	6909-6917	response	_
44-38	6918-6919	)	_
44-39	6920-6921	.	_

45-1	6922-6928	Second	_
45-2	6929-6930	,	_
45-3	6931-6933	as	_
45-4	6934-6936	in	_
45-5	6937-6938	,	_
45-6	6939-6947	spectral	_
45-7	6948-6956	measures	_
45-8	6957-6961	were	_
45-9	6962-6966	used	_
45-10	6967-6969	to	_
45-11	6970-6976	assess	_
45-12	6977-6980	the	_
45-13	6981-6986	power	_
45-14	6987-6988	,	_
45-15	6989-6994	phase	_
45-16	6995-7004	stability	_
45-17	7005-7006	,	_
45-18	7007-7010	and	_
45-19	7011-7018	spatial	_
45-20	7019-7031	distribution	_
45-21	7032-7034	of	_
45-22	7035-7038	the	_
45-23	7039-7043	vSSR	_
45-24	7044-7048	over	_
45-25	7049-7053	time	_
45-26	7054-7060	before	_
45-27	7061-7064	and	_
45-28	7065-7071	during	_
45-29	7072-7075	the	_
45-30	7076-7087	Preparatory	_
45-31	7088-7094	Period	_
45-32	7095-7096	(	_
45-33	7097-7103	−500ms	_
45-34	7104-7106	to	_
45-35	7107-7113	5000ms	_
45-36	7114-7116	in	_
45-37	7117-7125	relation	_
45-38	7126-7128	to	_
45-39	7129-7136	stimuli	_
45-40	7137-7142	onset	_
45-41	7143-7144	)	_
45-42	7145-7146	.	_

46-1	7147-7150	For	_
46-2	7151-7154	all	_
46-3	7155-7163	analyses	_
46-4	7164-7165	,	_
46-5	7166-7184	Greenhouse-Geisser	_
46-6	7185-7195	correction	_
46-7	7196-7199	was	_
46-8	7200-7204	used	_
46-9	7205-7209	when	_
46-10	7210-7220	sphericity	_
46-11	7221-7224	was	_
46-12	7225-7233	violated	_
46-13	7234-7235	.	_

47-1	7236-7239	All	_
47-2	7240-7248	analyses	_
47-3	7249-7253	were	_
47-4	7254-7264	replicated	_
47-5	7265-7267	as	_
47-6	7268-7269	a	_
47-7	7270-7278	function	_
47-8	7279-7281	of	_
47-9	7282-7293	subgrouping	_
47-10	7294-7303	psychosis	_
47-11	7304-7309	cases	_
47-12	7310-7312	by	_
47-13	7313-7321	clinical	_
47-14	7322-7336	symptomatology	_
47-15	7337-7338	(	_
47-16	7339-7342	see	_
47-17	7343-7355	Supplemental	_
47-18	7356-7363	Results	_
47-19	7364-7365	)	_
47-20	7366-7367	.	_

48-1	7368-7373	2.3.1	http://maven.renci.org/NeuroBridge/neurobridge#Thing
48-2	7374-7375	.	_

49-1	7376-7382	Visual	_
49-2	7383-7389	Evoked	_
49-3	7390-7400	Potentials	_
49-4	7401-7404	The	_
49-5	7405-7412	voltage	_
49-6	7413-7417	data	_
49-7	7418-7422	were	_
49-8	7423-7427	used	_
49-9	7428-7430	to	_
49-10	7431-7435	test	_
49-11	7436-7439	for	_
49-12	7440-7451	differences	_
49-13	7452-7454	in	_
49-14	7455-7460	brain	_
49-15	7461-7472	activations	_
49-16	7473-7474	,	_
49-17	7475-7477	at	_
49-18	7478-7481	the	_
49-19	7482-7491	beginning	_
49-20	7492-7494	of	_
49-21	7495-7501	visual	_
49-22	7502-7512	processing	_
49-23	7513-7515	at	_
49-24	7516-7527	Preparatory	_
49-25	7528-7534	Period	_
49-26	7535-7540	onset	_
49-27	7541-7542	,	_
49-28	7543-7550	between	_
49-29	7551-7554	the	_
49-30	7555-7559	pro-	_
49-31	7560-7563	and	_
49-32	7564-7576	anti-saccade	_
49-33	7577-7587	conditions	_
49-34	7588-7591	and	_
49-35	7592-7599	between	_
49-36	7600-7606	groups	_
49-37	7607-7608	(	_
49-38	7609-7615	Figure	_
49-39	7616-7617	2	_
49-40	7618-7619	)	_
49-41	7620-7621	,	_
49-42	7622-7627	using	_
49-43	7628-7635	methods	_
49-44	7636-7645	identical	_
49-45	7646-7648	to	_
49-46	7649-7657	previous	_
49-47	7658-7662	work	_
49-48	7663-7664	(	_
49-49	7665-7666	;	_
49-50	7667-7671	also	_
49-51	7672-7675	see	_
49-52	7676-7688	Supplemental	_
49-53	7689-7698	Materials	_
49-54	7699-7700	)	_
49-55	7701-7702	.	_

50-1	7703-7708	2.4.2	_
50-2	7709-7710	.	_

51-1	7711-7719	Spectral	_
51-2	7720-7728	measures	_
51-3	7729-7736	Similar	_
51-4	7737-7739	to	_
51-5	7740-7748	previous	_
51-6	7749-7753	work	_
51-7	7754-7759	using	_
51-8	7760-7769	paradigms	_
51-9	7770-7780	comparable	_
51-10	7781-7783	to	_
51-11	7784-7789	those	_
51-12	7790-7794	used	_
51-13	7795-7797	in	_
51-14	7798-7801	the	_
51-15	7802-7809	present	_
51-16	7810-7815	study	_
51-17	7816-7817	,	_
51-18	7818-7821	the	_
51-19	7822-7826	vSSR	_
51-20	7827-7830	was	_
51-21	7831-7841	quantified	_
51-22	7842-7847	using	_
51-23	7848-7859	inter-trial	_
51-24	7860-7865	phase	_
51-25	7866-7875	coherence	_
51-26	7876-7877	(	_
51-27	7878-7881	ITC	_
51-28	7882-7883	;	_
51-29	7884-7893	increased	_
51-30	7894-7906	across-trial	_
51-31	7907-7912	phase	_
51-32	7913-7923	similarity	_
51-33	7924-7926	of	_
51-34	7927-7930	the	_
51-35	7931-7934	EEG	_
51-36	7935-7942	signals	_
51-37	7943-7945	in	_
51-38	7946-7954	relation	_
51-39	7955-7957	to	_
51-40	7958-7967	frequency	_
51-41	7968-7970	of	_
51-42	7971-7977	visual	_
51-43	7978-7988	flickering	_
51-44	7989-7996	stimuli	_
51-45	7997-7998	)	_
51-46	7999-8002	and	_
51-47	8003-8015	single-trial	_
51-48	8016-8021	power	_
51-49	8022-8023	(	_
51-50	8024-8027	STP	_
51-51	8028-8029	)	_
51-52	8030-8031	.	_

52-1	8032-8035	ITC	_
52-2	8036-8039	and	_
52-3	8040-8043	STP	_
52-4	8044-8046	of	_
52-5	8047-8050	the	_
52-6	8051-8063	steady-state	_
52-7	8064-8072	response	_
52-8	8073-8079	across	_
52-9	8080-8084	time	_
52-10	8085-8089	were	_
52-11	8090-8099	estimated	_
52-12	8100-8102	by	_
52-13	8103-8110	complex	_
52-14	8111-8123	demodulation	_
52-15	8124-8126	at	_
52-16	8127-8130	the	_
52-17	8131-8141	flickering	_
52-18	8142-8147	rates	_
52-19	8148-8149	(	_
52-20	8150-8152	12	_
52-21	8153-8156	and	_
52-22	8157-8159	15	_
52-23	8160-8162	Hz	_
52-24	8163-8164	)	_
52-25	8165-8170	using	_
52-26	8171-8180	published	_
52-27	8181-8188	methods	_
52-28	8189-8190	(	_
52-29	8191-8192	;	_
52-30	8193-8197	also	_
52-31	8198-8201	see	_
52-32	8202-8214	Supplemental	_
52-33	8215-8224	Materials	_
52-34	8225-8226	)	_
52-35	8227-8228	.	_

53-1	8229-8237	Spectral	_
53-2	8238-8244	values	_
53-3	8245-8248	for	_
53-4	8249-8252	the	_
53-5	8253-8256	two	_
53-6	8257-8264	driving	_
53-7	8265-8276	frequencies	_
53-8	8277-8281	were	_
53-9	8282-8291	initially	_
53-10	8292-8300	analyzed	_
53-11	8301-8313	individually	_
53-12	8314-8317	but	_
53-13	8318-8322	were	_
53-14	8323-8328	later	_
53-15	8329-8335	summed	_
53-16	8336-8338	as	_
53-17	8339-8348	frequency	_
53-18	8349-8352	did	_
53-19	8353-8356	not	_
53-20	8357-8371	systematically	_
53-21	8372-8380	interact	_
53-22	8381-8385	with	_
53-23	8386-8391	group	_
53-24	8392-8393	,	_
53-25	8394-8398	task	_
53-26	8399-8400	,	_
53-27	8401-8403	or	_
53-28	8404-8408	time	_
53-29	8409-8410	.	_

54-1	8411-8414	ITC	_
54-2	8415-8421	values	_
54-3	8422-8426	were	_
54-4	8427-8435	averaged	_
54-5	8436-8440	over	_
54-6	8441-8442	9	_
54-7	8443-8452	posterior	_
54-8	8453-8459	cortex	_
54-9	8460-8467	sensors	_
54-10	8468-8477	capturing	_
54-11	8478-8482	peak	_
54-12	8483-8487	vSSR	_
54-13	8488-8496	activity	_
54-14	8497-8498	(	_
54-15	8499-8511	Supplemental	_
54-16	8512-8518	Figure	_
54-17	8519-8520	1	_
54-18	8521-8522	)	_
54-19	8523-8524	,	_
54-20	8525-8533	averaged	_
54-21	8534-8538	from	_
54-22	8539-8547	−500:0ms	_
54-23	8548-8560	pre-stimulus	_
54-24	8561-8564	and	_
54-25	8565-8569	over	_
54-26	8570-8574	each	_
54-27	8575-8577	of	_
54-28	8578-8581	the	_
54-29	8582-8586	five	_
54-30	8587-8591	1sec	_
54-31	8592-8603	Preparatory	_
54-32	8604-8610	Period	_
54-33	8611-8621	countdowns	_
54-34	8622-8623	,	_
54-35	8624-8627	and	_
54-36	8628-8636	analyzed	_
54-37	8637-8642	using	_
54-38	8643-8648	mixed	_
54-39	8649-8656	effects	_
54-40	8657-8662	3-way	_
54-41	8663-8670	MANOVAs	_
54-42	8671-8672	(	_
54-43	8673-8678	Group	_
54-44	8679-8680	×	_
54-45	8681-8688	Saccade	_
54-46	8689-8693	Type	_
54-47	8694-8695	×	_
54-48	8696-8700	Time	_
54-49	8701-8704	Bin	_
54-50	8705-8706	)	_
54-51	8707-8711	with	_
54-52	8712-8716	post	_
54-53	8717-8720	hoc	_
54-54	8721-8726	Tukey	_
54-55	8727-8735	honestly	_
54-56	8736-8747	significant	_
54-57	8748-8758	difference	_
54-58	8759-8764	tests	_
54-59	8765-8766	.	_

55-1	8767-8769	To	_
55-2	8770-8774	most	_
55-3	8775-8785	accurately	_
55-4	8786-8789	and	_
55-5	8790-8805	comprehensively	_
55-6	8806-8813	capture	_
55-7	8814-8817	the	_
55-8	8818-8824	shared	_
55-9	8825-8833	variance	_
55-10	8834-8836	in	_
55-11	8837-8844	spatial	_
55-12	8845-8857	topographies	_
55-13	8858-8860	of	_
55-14	8861-8864	STP	_
55-15	8865-8871	across	_
55-16	8872-8876	time	_
55-17	8877-8878	,	_
55-18	8879-8886	spatial	_
55-19	8887-8890	PCA	_
55-20	8891-8894	was	_
55-21	8895-8906	implemented	_
55-22	8907-8912	using	_
55-23	8913-8916	the	_
55-24	8917-8920	ERP	_
55-25	8921-8924	PCA	_
55-26	8925-8932	Toolkit	_
55-27	8933-8935	in	_
55-28	8936-8942	Matlab	_
55-29	8943-8944	(	_
55-30	8945-8954	Mathworks	_
55-31	8955-8956	,	_
55-32	8957-8963	Matick	_
55-33	8964-8965	,	_
55-34	8966-8968	MA	_
55-35	8969-8970	)	_
55-36	8971-8972	.	_

56-1	8973-8976	For	_
56-2	8977-8981	each	_
56-3	8982-8987	group	_
56-4	8988-8991	and	_
56-5	8992-8996	task	_
56-6	8997-9009	individually	_
56-7	9010-9011	,	_
56-8	9012-9017	power	_
56-9	9018-9024	values	_
56-10	9025-9029	from	_
56-11	9030-9041	−500:5000ms	_
56-12	9042-9046	were	_
56-13	9047-9059	standardized	_
56-14	9060-9066	across	_
56-15	9067-9074	sensors	_
56-16	9075-9081	before	_
56-17	9082-9091	averaging	_
56-18	9092-9098	across	_
56-19	9099-9107	subjects	_
56-20	9108-9109	.	_

57-1	9110-9115	Scree	_
57-2	9116-9121	tests	_
57-3	9122-9125	for	_
57-4	9126-9130	each	_
57-5	9131-9141	identified	_
57-6	9142-9145	one	_
57-7	9146-9155	component	_
57-8	9156-9157	.	_

58-1	9158-9161	The	_
58-2	9162-9169	spatial	_
58-3	9170-9182	distribution	_
58-4	9183-9186	and	_
58-5	9187-9193	amount	_
58-6	9194-9196	of	_
58-7	9197-9205	variance	_
58-8	9206-9215	accounted	_
58-9	9216-9219	for	_
58-10	9220-9224	were	_
58-11	9225-9231	nearly	_
58-12	9232-9241	identical	_
58-13	9242-9243	(	_
58-14	9244-9247	all	_
58-15	9248-9260	correlations	_
58-16	9261-9268	greater	_
58-17	9269-9273	than	_
58-18	9274-9275	r	_
58-19	9276-9277	=	_
58-20	9278-9282	.975	_
58-21	9283-9284	)	_
58-22	9285-9286	,	_
58-23	9287-9289	so	_
58-24	9290-9293	the	_
58-25	9294-9298	same	_
58-26	9299-9308	procedure	_
58-27	9309-9312	was	_
58-28	9313-9321	repeated	_
58-29	9322-9324	on	_
58-30	9325-9326	a	_
58-31	9327-9333	single	_
58-32	9334-9339	grand	_
58-33	9340-9347	average	_
58-34	9348-9352	time	_
58-35	9353-9359	course	_
58-36	9360-9361	,	_
58-37	9362-9371	resulting	_
58-38	9372-9374	in	_
58-39	9375-9376	a	_
58-40	9377-9386	component	_
58-41	9387-9397	accounting	_
58-42	9398-9401	for	_
58-43	9402-9406	48.6	_
58-44	9407-9408	%	_
58-45	9409-9411	of	_
58-46	9412-9420	variance	_
58-47	9421-9422	(	_
58-48	9423-9426	see	_
58-49	9427-9439	Supplemental	_
58-50	9440-9446	Figure	_
58-51	9447-9448	2	_
58-52	9449-9450	)	_
58-53	9451-9452	.	_

59-1	9453-9462	Component	_
59-2	9463-9470	weights	_
59-3	9471-9475	were	_
59-4	9476-9486	multiplied	_
59-5	9487-9489	by	_
59-6	9490-9494	each	_
59-7	9495-9502	subject	_
59-8	9503-9504	’	_
59-9	9505-9506	s	_
59-10	9507-9511	data	_
59-11	9512-9513	,	_
59-12	9514-9520	summed	_
59-13	9521-9527	across	_
59-14	9528-9535	sensors	_
59-15	9536-9537	,	_
59-16	9538-9541	and	_
59-17	9542-9549	divided	_
59-18	9550-9552	by	_
59-19	9553-9556	the	_
59-20	9557-9565	absolute	_
59-21	9566-9572	square	_
59-22	9573-9576	sum	_
59-23	9577-9579	of	_
59-24	9580-9583	the	_
59-25	9584-9593	component	_
59-26	9594-9601	weights	_
59-27	9602-9603	,	_
59-28	9604-9612	reducing	_
59-29	9613-9616	STP	_
59-30	9617-9626	waveforms	_
59-31	9627-9631	from	_
59-32	9632-9634	64	_
59-33	9635-9636	(	_
59-34	9637-9640	one	_
59-35	9641-9644	for	_
59-36	9645-9649	each	_
59-37	9650-9656	sensor	_
59-38	9657-9658	)	_
59-39	9659-9661	to	_
59-40	9662-9663	1	_
59-41	9664-9667	for	_
59-42	9668-9672	each	_
59-43	9673-9684	participant	_
59-44	9685-9686	.	_

60-1	9687-9690	STP	_
60-2	9691-9699	averaged	_
60-3	9700-9704	over	_
60-4	9705-9708	the	_
60-5	9709-9715	entire	_
60-6	9716-9722	5500ms	_
60-7	9723-9727	time	_
60-8	9728-9734	course	_
60-9	9735-9743	provided	_
60-10	9744-9745	a	_
60-11	9746-9753	measure	_
60-12	9754-9756	of	_
60-13	9757-9766	intrinsic	_
60-14	9767-9775	activity	_
60-15	9776-9779	and	_
60-16	9780-9784	were	_
60-17	9785-9794	subjected	_
60-18	9795-9797	to	_
60-19	9798-9799	a	_
60-20	9800-9805	2-way	_
60-21	9806-9811	ANOVA	_
60-22	9812-9813	(	_
60-23	9814-9819	Group	_
60-24	9820-9821	×	_
60-25	9822-9829	Saccade	_
60-26	9830-9834	Type	_
60-27	9835-9836	)	_
60-28	9837-9841	with	_
60-29	9842-9846	post	_
60-30	9847-9850	hoc	_
60-31	9851-9856	Tukey	_
60-32	9857-9865	honestly	_
60-33	9866-9877	significant	_
60-34	9878-9888	difference	_
60-35	9889-9894	tests	_
60-36	9895-9896	.	_

61-1	9897-9905	Averaged	_
61-2	9906-9912	values	_
61-3	9913-9916	for	_
61-4	9917-9921	each	_
61-5	9922-9924	of	_
61-6	9925-9928	the	_
61-7	9929-9933	five	_
61-8	9934-9938	1sec	_
61-9	9939-9950	Preparatory	_
61-10	9951-9957	Period	_
61-11	9958-9968	countdowns	_
61-12	9969-9973	were	_
61-13	9974-9993	baseline-subtracted	_
61-14	9994-9997	and	_
61-15	9998-10006	analyzed	_
61-16	10007-10012	using	_
61-17	10013-10014	a	_
61-18	10015-10020	mixed	_
61-19	10021-10028	effects	_
61-20	10029-10034	3-way	_
61-21	10035-10042	MANOVAs	_
61-22	10043-10044	(	_
61-23	10045-10050	Group	_
61-24	10051-10052	×	_
61-25	10053-10060	Saccade	_
61-26	10061-10065	Type	_
61-27	10066-10067	×	_
61-28	10068-10072	Time	_
61-29	10073-10076	Bin	_
61-30	10077-10078	)	_
61-31	10079-10083	with	_
61-32	10084-10088	post	_
61-33	10089-10092	hoc	_
61-34	10093-10098	Tukey	_
61-35	10099-10107	honestly	_
61-36	10108-10119	significant	_
61-37	10120-10130	difference	_
61-38	10131-10136	tests	_
61-39	10137-10138	.	_

62-1	10139-10146	Induced	_
62-2	10147-10152	power	_
62-3	10153-10156	was	_
62-4	10157-10161	also	_
62-5	10162-10170	examined	_
62-6	10171-10173	as	_
62-7	10174-10176	an	_
62-8	10177-10188	alternative	_
62-9	10189-10196	measure	_
62-10	10197-10199	of	_
62-11	10200-10209	intrinsic	_
62-12	10210-10216	neural	_
62-13	10217-10225	activity	_
62-14	10226-10227	,	_
62-15	10228-10232	with	_
62-16	10233-10240	results	_
62-17	10241-10248	similar	_
62-18	10249-10251	to	_
62-19	10252-10257	those	_
62-20	10258-10260	of	_
62-21	10261-10264	STP	_
62-22	10265-10266	(	_
62-23	10267-10270	see	_
62-24	10271-10283	Supplemental	_
62-25	10284-10293	Materials	_
62-26	10294-10295	)	_
62-27	10296-10297	.	_

